Alnylam Pharmaceuticals said this week that it has appointed Robert Millman as chief patent counsel.
Millman, who has served as a consultant to Alnylam since June 2003, will be responsible for directing all aspects of the company’s intellectual property activities, said Alnylam.
According to the company, Millman was most recently a freelance IP consultant for biotechnology companies, and served as interim chief patent counsel at Infinity Pharmaceuticals. He has also served as chief IP counsel at Celera Genomics, and patent counsel at Millennium Pharmaceuticals.
Millman received a JD from Washington College of Law at the American University, an MS in genetics from Washington State University, and a BS in biochemistry from the University of California, Riverside, said Alnylam.
CytoGenix said this week that Kurt Berens has joined the company as vice president of product development.
Berens was previously a section manager for Wyle Laboratories, cellular and biomedial group at NASA-Johnson Space Center, said CytoGenix. Before this, he served as senior project manager for clinical development and regulatory affairs at Texas Biotechnology.
Cyntellect has recently appointed Jim Linton as the company’s chief business officer.
Linton most recently served as vice president of business affairs and business development at Protometrix, which was acquired in April by Invitrogen. He holds a PhD in genetics from Emory University, and an MBA from the University of California, Davis.
Genospectra said this week that Ron Hahn has joined the company’s board of directors.
Hahn is a partner at venture fund Battelle Ventures. His new position at Genospectra comes in connection with Battelle’s participation in Genospectra’s series C round of financing.